A novel RNA sequencing-based miRNA signature predicts with recurrence and outcome of hepatocellular carcinoma.

ABSTRACT: Hepatocellular carcinoma (HCC) is the fifth most common type of cancer and the second leading cause of cancer-related deaths worldwide. Given that the rate of HCC recurrence 5 years after liver resection is as high as 70%, patient with HCC typically has a poor outcome. A biomarker or set of biomarkers that could predict disease recurrence would have a substantial clinical impact, allowing earlier detection of recurrence and more effective treatment. With the aim of identifying a new microRNA (miRNA) signature associated with HCC recurrence, we analyzed data on 306 patients with HCC for whom both miRNA expression profiles and complete clinical information were available from The Cancer Genome Atlas database. Through this analysis, we identified a six-miRNA signature that could effectively p

SUBMITTER: Bai F 

PROVIDER: S-EPMC6026871 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature